Exclusive

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

  • by

Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life… Read More »BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002